Amanote Research
Register
Sign In
Drotrecogin Alfa Activated as a Treatment for Severe Sepsis in Pediatric Cancer
Bone Marrow Transplantation
- United Kingdom
doi 10.1038/sj.bmt.1705483
Full Text
Open PDF
Abstract
Available in
full text
Categories
Transplantation
Hematology
Date
August 21, 2006
Authors
G Russo
M La Spina
N Disma
M Astuto
Publisher
Springer Nature
Related search
Introduction: Severe Sepsis and Drotrecogin Alfa (Activated)
Critical Care
Critical Care
Intensive Care Medicine
Drotrecogin Alfa (Activated) May Attenuate Severe Sepsis-Associated Encephalopathy in Clinical Septic Shock
Critical Care
Critical Care
Intensive Care Medicine
Drotrecogin Alfa (Activated)
European Journal of Anaesthesiology
Anesthesiology
Pain Medicine
Drotrecogin Alfa in Patients With Severe Sepsis: Experience From a Tertiary Care Center in North India
Critical Care
Critical Care
Intensive Care Medicine
The Safety Profile of Drotrecogin Alfa (Activated)
Critical Care
Critical Care
Intensive Care Medicine
Early Drotrecogin Alpha (Activated) Administration in Severe Sepsis Is Associated With Lower Mortality: A Retrospective Analysis of the Canadian ENHANCE Cohort
Critical Care
Critical Care
Intensive Care Medicine
Activated Protein C in Severe Sepsis
Intensive and Critical Care Nursing
Critical Care Nursing
Protocolized Treatment Is Associated With Decreased Organ Dysfunction in Pediatric Severe Sepsis*
Pediatric Critical Care Medicine
Child Health
Critical Care
Pediatrics
Perinatology
Intensive Care Medicine
Management and Treatment Guidelines for Sepsis in Pediatric Patients
The Open Inflammation Journal
